N-(3-chloro-4-cyano-phenyl)-2-methyl-oxirane-2-carboxamide | 1010827-25-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-chloro-4-cyano-phenyl)-2-methyl-oxirane-2-carboxamide
• 英文别名: N-(3-chloro-4-cyanophenyl)-2-methyloxirane-2-carboxamide
• CAS: 1010827-25-4
• 化学式: C₁₁H₉ClN₂O₂
• 分子量: 236.658
• InChiKey: AEQOIHPWZZNUCZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  65.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N-(3-chloro-4-cyano-phenyl)-2-methyl-prop-2-enamide 在 2,6-二叔丁基-4-甲基苯酚 、 间氯过氧苯甲酸 作用下， 以 三氯乙烷 为溶剂， 反应 4.0h， 以31%的产率得到N-(3-chloro-4-cyano-phenyl)-2-methyl-oxirane-2-carboxamide
  参考文献：
  名称：

  WO2008/44033

  摘要：

  公开号：

文献信息

• [EN] SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF<br/>[FR] LIGANDS DE SARD - COMPOSÉS DE DÉGRADATION SÉLECTIFS DES RÉCEPTEURS AUX ANDROGÈNES - ET MÉTHODES D'UTILISATION
  申请人：GTX INC

  公开号：WO2016172358A1

  公开（公告）日：2016-10-27

  This invention provides novel indole, indazole, benzimidazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic and/or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

  这项发明提供了新型吲哚、吲哚唑、苯并咪唑、吲哚啉、喹啉、异喹啉和咔唑选择性雄激素受体降解剂（SARD）化合物，以及在治疗前列腺癌、晚期前列腺癌、去势抵抗性前列腺癌、雄激素性脱发或其他高雄激素皮肤疾病、肯尼迪病、肌萎缩侧索硬化（ALS）和子宫肌瘤方面的药物组合物和用途，以及用于降低受试者体内雄激素受体全长（AR-FL）包括病原性和/或耐药突变、AR剪接变体（AR-SV）和AR病原性多谷氨酸（polyQ）多态性的水平的方法。
• SUBSTITUTED ACYLANILIDES AND METHODS OF USE THEREOF
  申请人：University of Tennessee Research Foundation

  公开号：US20160089356A1

  公开（公告）日：2016-03-31

  This invention provides substituted acylanilide compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter alia, a muscle wasting disease and/or disorder such as muscular dystrophies including Duchenne muscular dystrophy and Becker muscular dystrophy.

  该发明提供了取代的酰基苯胺化合物及其在治疗受试者中的多种疾病或病况中的应用，包括但不限于肌肉消耗性疾病和/或疾病，如包括杜氏肌萎缩症和贝克肌萎缩症的肌萎缩症。
• COMPOUND FOR TREATING BREAST CANCER AND PROGESTIN-DEPENDENT CONDITIONS
  申请人：University of Tennessee Research Foundation

  公开号：EP3147278A1

  公开（公告）日：2017-03-29

  This invention provides a pharmaceutical composition comprising a compound of formula S-(I): or its isomer, pharmaceutically acceptable salt, pharmaceutical product, crystal, N-oxide, hydrate or any combination thereof, for use in treating or preventing breast cancer in a subject.

  本发明提供了一种包含式 S-(I)化合物的药物组合物： 或其异构体、药学上可接受的盐、药剂制品、晶体、N-氧化物、水合物或其任意组合，用于治疗或预防受试者的乳腺癌。
• Selective androgen receptor degrader (SARD) ligands and methods of use thereof
  申请人：GTx, Inc.

  公开号：US10017471B2

  公开（公告）日：2018-07-10

  This invention provides novel indole, indazole, benzimidazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other AR-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels (through degradation) and/or activity (through inhibition) of any androgen receptor including androgen receptor-full length (AR-FL) including pathogenic and/or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

  本发明提供了新型吲哚、吲唑、苯并咪唑、吲哚啉、喹诺酮、异喹啉和咔唑选择性雄激素受体降解剂（SARD）化合物、药物组合物及其在治疗前列腺癌、晚期前列腺癌、阉割耐药前列腺癌、其他表达AR的癌症、雄激素性脱发或其他高雄激素性皮肤病、肯尼迪病、肌萎缩性脊髓侧索硬化症（ALS）、腹主动脉瘤（AAA）和子宫肌瘤中的用途，以及降低其水平（通过降解）的方法、肌萎缩性脊髓侧索硬化症（ALS）、腹主动脉瘤（AAA）和子宫肌瘤，以及降低受试者体内任何雄激素受体的水平（通过降解）和/或活性（通过抑制）的方法，包括雄激素受体全长（AR-FL），包括致病性和/或抗性突变、AR-剪接变体（AR-SV）和致病性多谷氨酰胺（polyQ）多态性。
• Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
  申请人：GTx, Inc.

  公开号：US10441570B2

  公开（公告）日：2019-10-15

  This invention provides novel indole, indazole, benzimidazole, benzotriazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating hyperproliferations of the prostate including pre-malignancies and benign prostatic hyperplasia, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other AR-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels (through degradation) and/or activity (through inhibition) of any androgen receptor including androgen receptor-full length (AR-FL) including pathogenic and/or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

  本发明提供了新型吲哚、吲唑、苯并咪唑、苯并三唑、吲哚啉、喹诺酮、异喹啉和咔唑选择性雄激素受体降解剂（SARD）化合物、药物组合物及其在治疗前列腺过度增生（包括恶性肿瘤前期和良性前列腺增生）、前列腺癌、晚期前列腺癌、阉割抵抗性前列腺癌、其他AR表达癌症中的用途、雄激素性脱发或其他高雄激素性皮肤病、肯尼迪病、肌萎缩性脊髓侧索硬化症（ALS）、腹主动脉瘤（AAA）和子宫肌瘤、以及降低受试者体内包括雄激素受体全长（AR-FL）在内的任何雄激素受体的水平（通过降解）和/或活性（通过抑制）的方法，包括致病性和/或抗性突变、AR-剪接变体（AR-SV）和致病性多聚谷氨酰胺（polyQ）多态性。